Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Portfolio Pulse from
Levi & Korsinsky law firm has initiated a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 27, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics is subject to a class action lawsuit alleging securities fraud related to its NTLA-3001 program, which was unexpectedly halted, leading to a stock price decline and 27% workforce reduction.
The lawsuit and unexpected program discontinuation suggest significant operational challenges, which could negatively impact investor confidence and stock performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100